Incyte Announces Change to its Board of Directors

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Change to its Board of Directors.

Business Wire • Dec 12, 2025

Here's Why Incyte (INCY) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Dec 11, 2025

Calls of the Day: Netflix, Thermo Fisher, Incyte and Shake Shack

The Investment Committee debate the latest Calls of the Day.

CNBC Television • Dec 9, 2025

Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status

INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.

Zacks Investment Research • Dec 8, 2025

Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in ET.

Business Wire • Dec 8, 2025

Incyte Gets FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug

The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock is basing near five-year highs.

Investors Business Daily • Dec 7, 2025

Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH Transcript

Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH Transcript

Seeking Alpha • Dec 7, 2025

Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA.

Business Wire • Dec 7, 2025

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with MF Presented at ASH 2025.

Business Wire • Dec 7, 2025

Incyte: Buy At This Inflection Point

Incyte Corporation's rapid non-Jakafi portfolio growth and strong operating leverage look decent amid still-cheap valuation, supporting attractive risk-reward over the coming quarters ahead. Q3 revenue beat consensus by 9%, with Jakafi still 58% of sales as rapidly expanding Opzelura, Niktimvo, Monjuvi, and Zynyz materially de-risking concentration on Jakafi. Management guides for flat OpEx and rising revenues into FY2025, supporting sustained margin expansion and robust EPS growth potential post-2029.

Seeking Alpha • Dec 6, 2025